Académique Documents
Professionnel Documents
Culture Documents
Dr.Hj.RikaYuliwulandari,PhD
Types of s (focal)
Primary
Definition
Epilepsy:
Recurrentseizuredisorders Sudden Excessive Symptomsdependonthesiteofelectricaldischarge
Antiepilepticdrugs:
Treat50%ofpatientwithconvulsion Tappering on tappering off Mekanisme:blok inisiasi lonjakan elektrik dari focalareaatau mencegah penyebaran lonjakan elektrik abnormalke areaotak lainnya Goal:
Stopconvulsion Notharmfulforcerebralneurons Normalactivityposttreatment
PrincipleMechanismsofActionof AntiepilepticDrugs
DecreaseactivityofvoltagedependentNa+ channels DecreaseactivityofvoltagedependentCa+ channels AugmentGABA activity Decreaseglutamatereceptoractivity Drugtreatmentdeppends onthespecifictype ofseizure
ClinicalApplicationof AntiepilepticDrugs
Typesofepilepsy PARTIAL Simple Complex GENERALIZED TonicClonic (grandmal) Absence(Petit mal) Myoclonic Febrile Seizures inchildren Status epilepticus Phenytoin, CBZ Ethosuximide Valproic acid, Clonazepam Phenobarbital Phenitoin,Diazepam Primidone Phenobarbital Phenobarbital,Primidone,Valproic acid Valproic acid,Clonazepam Phenitoin,CBZ Phenitoin,CBZ Phenobarbital,Primidone Primidone Drugs1 Drugs2
WhentoWithdrawAntiepilepticDrugs?
Phenytoin
Hydantoin group
Phenytoin (Dephenylhydantoin) Mefenytoin Etotoin
Pharmacology:
Nafluxinneurons stabilizesneuronalmembranesto depolarization Ca influx Effect:Drowsiness,lethargywithouthypnosis Absorption:slow(i.m.isdepositedininjectionsitefor5days) Distributionisrapid Highconcentrationinbrain Mostlyboundtoplasmaalbumin T1/2:742hrs Proteinbinding:90%
Carbamazepine
Moa:blockingNachannel inhibitpropagationofabnormalimpulsesin thebrain Pharmacology:
Absorption:slow Highlipidsolubility rapidlyenterthebrain EnhancehepaticP450system inchronicadministration,t1/2decrease Dose:4001200mg(Child:1030mg/kgbw) T1/2:824hrs Proteinbinding:75% Poonly Se:
Chronicuse:stupor,coma,respiratorydepression,drowsiness,vertigo,ataxia,blurred vision GIproblem:nausea,vomiting Aplastic anemia,agranulocytosis,thrombocytopenia Potentiallyinducelivertoxicity(needfrequentliverfunctiontest!!!!)
Druginteraction:
Phenobarbital
Familyofbarbiturate:
Phenobarbital Primidone
Pharmacology:
Moa:Potentiateinhibiton effectofGABA (gammaaminobutyric acid)mediatedneurons Absorption:
Oral:wellabsorbed PotentinducerofP450 Almost75%isinactivatedinliver,therestisexcretedthroughkidney
Se:
Sedation,ataxia,nystagmus,vertigo,acutepsychoticreactions Sensitiveindividual:nausea,vomiting,morbiliform rash Highdose:agitation,confusion Discontinuation:reboundseizures
Primidone
ResemblesPhenobarbital Orallywellabsorbed Poorproteinbinding
Valproic acid
Moa:enhanceGABA actionatinhibitorysynapses Uses:mosteffectiveformyoclonic seizures Pharmacology:
Orallywellandrapidabsorbed Proteinbinding:90% 3%excretedunchanged,therestbecomeactivemetabolite MetabolizedinliverbyP450system Dose:7503000mg(child:1560mg/kgbw) T1/2:616hrs Se:
nausea,vomiting,sedation,ataxia,tremor Rashandalopeciainsomeindividuals Increasebleedingtimeduetothrombocytopeniaandinhibitionofplatelet aggregation
Druginteraction:
Inhibitsphenobarbital metabolismcausingincreasecirculatinglevelofthe drug
Ethosuximide
FamilyofSuximide
Ethosuximide,Metsuximide,Fensuximide
Pharmacology:
Moa:inhibitCachannelinneuronTcellofthalamus Wellabsorbedorally Proteinbinding:0% 25%excretedunchangedinurine 75%isinactivatedinliver DoesnotinduceP450system Dose:5001500mg(child:1530mg/kgbw) T:2060hrs Se:
stomachirritation,nausea,vomiting,drowsiness,lethargy,dixxiness, restlessness,agitation,anxiety,inabilitytoconcentrate Sensitiveindividual:StevensJohnsonssyndrome,urticatia,leukopenia, aplastic anemia,thrombocytopenia
Diazepam
FamilyofBenzodiazepine
Diazepam,Klonazepam,Nitrazepam
Pharmacology:
Docofacutetreatmentinstatusepilepticus Dose:
520mgiv(slow) canberepeatedafter1520mnt Infant:0.5mg/kgbw perrectal,child<11yr:1mg/kgbw
Se:respiratorytractobstruction,respiratory depression,hypotension,cardiacarrest,sleepy
Otherantiepilepticdrugs
Gabapentin:
AnalogofGABA Proteinbinding:0% Excretedunchangedinurine minimizedruginteraction Dose:9003600mg T1/2:57hrs Se:mildCNS
Lamotrigine:
Moa:inhibitglutamateandaspartate release,blockssodiumchannels, preventsrepetitivefiring Proteinbinding:55% Metabolizedinliver Dose:100600mg T1/2:1570hrs Se:mildCNSeffect,rash Druginteraction:
T1/2isinhibitedbyP450enzymeinducingdrug(CBZ,Phenytoin) TisIncreasedbyvalproic acid
Read
Patophysiology ofconvulsion